European Scientists Receive Funding From Sixth EU Framework Program to develop novel therapy for cancer
Scientists of a consortium led by the University of Crete Medical School, Greece, have been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new therapeutic strategies for cancer.
The research program, code-named Apotherapy, will develop methods to activate a protein at the surface of ovarian, lung and bladder tumor cells which will stop their growth. This protein, called CD40, can also induce the destruction of malignant cells by the body’s own defences. The scientists who participate in the program aim to combine CD40 triggering with chemotherapy or with innovative drugs that will cut-off signals necessary for the survival of cancer cells. This strategy is expected to achieve maximal therapy with minimal side effects.
Dr Aristides Eliopoulos of the University of Crete Medical School who co-ordinates the Apotherapy research program, commented:
“We are delighted to have received funding under this program grant. It gives us the opportunity to collaborate with some of the top European scientists and oncologists to fight this deadly disease. We are confident that in the near future, we will be able to progress the best of our developed strategies into clinical practice for the benefit of cancer sufferers.”
The project integrates the core skills and expertise of academic scientists, oncologists and biotechnology researchers from a total of seven Institutions:
University of Crete Medical School, Greece;
University of Helsinki, Finland;
University College London, UK;
Istituto Mario Negri, Milan, Italy;
University of Olomouc, Czech Rep;
University of Uppsala, Sweden and
the biotechnology company Novosom AG, Germany.
Apotherapy is supported with € 2 million from the European Commission FP6 for a period of 3 years.
Apotherapy: CD40 ligand-based modalities for the treatment of solid tumors
Paivi Lehtinen | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...